Silexion Therapeutics Corp (SLXN)

Over the past six months, Silexion Therapeutics Corp.'s stock price has significantly declined. Key events impacting the stock include earnings reports, clinical trial progress and announcements, analyst ratings and price targets, and partnerships. The company announced Q3 2025 earnings of $3.3M, a 30.3% increase from the previous quarter. The latest earnings report on May 13, 2025, showed an EPS of -$3.9, missing the consensus estimate. Silexion released a CEO letter highlighting 2025 achievements and outlining 2026 milestones on January 6, 2026. Silexion submitted a Phase 2/3 trial application to Israel for SIL204 on December 16, 2025. Silexion completed toxicology studies for SIL204 on November 26, 2025. In July 2025, the company reported positive preclinical data for SIL204 in lung cancer. In April 2025, Silexion partnered with Catalent to advance SIL204 siRNA therapy. As of December 15, 2025, two analysts covering Silexion Therapeutics stock had a consensus rating of "Strong Buy" with an average price target of $40.5. On December 20, 2025, Silexion Therapeutics' price target was decreased by 25.00% to $9.18.

There is no specific information available regarding demand seasonality for Silexion Therapeutics Corp.'s products and services. Demand is primarily driven by clinical trial outcomes, regulatory approvals, and the prevalence of the targeted diseases.

Silexion Therapeutics Corp. is a biopharmaceutical company focused on RNAi-based cancer drugs and delivery systems for solid tumors, operating within the Healthcare sector. The company utilizes its proprietary LODER delivery platform. Its primary product candidates include SiG12D-LODER, Prostate-LODER, GBM-LODER and SIL-204. Silexion Therapeutics also collaborates with Evonik Corporation for advanced siRNA formulation development.

Silexion Therapeutics Corp. was founded in 2008 and is headquartered in Jerusalem, Israel.

Specific information detailing Silexion Therapeutics Corp.'s brand reputation in the past year is not readily available. The news primarily focuses on clinical trial progress, financial reports, and corporate announcements.

As of February 3, 2026, insider ownership of Silexion Therapeutics is 23.34%, and institutional ownership is 0.19%. Major institutional owners include Montag A & Associates Inc., SBI Securities Co., Ltd., UBS Group AG, Pflug Koory, LLC, Moringa Sponsor, LP, Lind Global Fund III LP, INTRACOASTAL CAPITAL, LLC, Orca Capital AG, Lincoln Alternative Strategies LLC and Wildcat Capital Management, LLC. Major individual owners (insiders) include Ilan Hadar, Amnon Peled, Leonard Potter, Ruth Alon, Ilan Levin, Mitchell Shirvan, Ilan Shiloah, Shlomo Noy, Hadar Mirit Horenshtein, Avner Lushi and Dror Yosef Abramov.